Results

RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/23163753http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/23163753http://www.w3.org/2000/01/rdf-schema#comment"

Aim

Matrix metalloproteinases (MMPs) have been considered to have a role in various pathological processes, including inflammatory response, cardiovascular disease and recently also in ovarian dysfunction. Since prolidase could be accepted as a matrix metalloproteinase, on the biochemical level, we aimed to evaluate serum prolidase activity and oxidative-antioxidative status in patients with polycystic ovary syndrome (PCOS) and healthy individuals.

Materials and methods

Thirty-three PCOS patients and 28 healthy nonhyperandrogenic women were studied. Levels of prolidase activity, total antioxidant status (TAS), total oxidant status (TOS), oxidative stress index (OSI), luteinizing hormone (LH), follicle-stimulating hormone (FSH), total testosterone (T) and prolactin (PRL) were calculated.

Results

Levels of prolidase activities, total oxidant status, oxidative stress index, LH, PRL, and T were significantly higher in PCOS group than in the control group. Total antioxidant status levels were lower in PCOS group than healthy group, but it was not statistically significant. There was no significant difference between PCOS and control groups in term of FSH.

Conclusion

Women with PCOS have increased serum prolidase activity and oxidative stress. It might be hypothesized that elevated serum prolidase activity and oxidative stress may be associated with increased cardiovascular risk in PCOS and/or menstrual irregularities associated with this syndrome."xsd:string
http://purl.uniprot.org/citations/23163753http://purl.org/dc/terms/identifier"doi:10.1111/cen.12110"xsd:string
http://purl.uniprot.org/citations/23163753http://purl.uniprot.org/core/author"Aksoy N."xsd:string
http://purl.uniprot.org/citations/23163753http://purl.uniprot.org/core/author"Camuzcuoglu H."xsd:string
http://purl.uniprot.org/citations/23163753http://purl.uniprot.org/core/author"Vural M."xsd:string
http://purl.uniprot.org/citations/23163753http://purl.uniprot.org/core/author"Camuzcuoglu A."xsd:string
http://purl.uniprot.org/citations/23163753http://purl.uniprot.org/core/author"Hilali N."xsd:string
http://purl.uniprot.org/citations/23163753http://purl.uniprot.org/core/date"2013"xsd:gYear
http://purl.uniprot.org/citations/23163753http://purl.uniprot.org/core/name"Clin Endocrinol (Oxf)"xsd:string
http://purl.uniprot.org/citations/23163753http://purl.uniprot.org/core/pages"105-110"xsd:string
http://purl.uniprot.org/citations/23163753http://purl.uniprot.org/core/title"Increased prolidase activity and oxidative stress in PCOS."xsd:string
http://purl.uniprot.org/citations/23163753http://purl.uniprot.org/core/volume"79"xsd:string
http://purl.uniprot.org/citations/23163753http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/23163753
http://purl.uniprot.org/citations/23163753http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/23163753
http://purl.uniprot.org/uniprot/#_A0A140VJR2-mappedCitation-23163753http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/23163753
http://purl.uniprot.org/uniprot/#_J3K000-mappedCitation-23163753http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/23163753
http://purl.uniprot.org/uniprot/#_P12955-mappedCitation-23163753http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/23163753
http://purl.uniprot.org/uniprot/A0A140VJR2http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/23163753
http://purl.uniprot.org/uniprot/P12955http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/23163753
http://purl.uniprot.org/uniprot/J3K000http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/23163753